

Figure S1. Correlations between the (A, C and E) uPA and (B, D and F) PAI-1 concentrations (measured using ELISA) and the corresponding gene (*PLAU* and *SERPINE1*, respectively) normalized expression levels (measured using *in situ* hybridization). uPA, urokinase plasminogen activator; PAI-1, plasminogen activator inhibitor type 1; IT, intra-tumor area; PT, peripheral zone.




Figure S2. Receiver operating characteristic curves constructed using the sensitivity-specificity relationship of the *in situ* hybridization assay for (A, C and E) uPA and (B, D and F) PAI-1 to discriminate uPA⁺ from uPA⁻ and PAI-1⁺ from PAI-1⁻ samples as assessed using ELISA. uPA, urokinase plasminogen activator; PAI-1, plasminogen activator inhibitor type 1; +, positive; -, negative; IT, intra-tumor area; PT, peripheral zone.

